Bayer reports Q3 core EPS EUR 0.57 vs. EUR 0.24 last year

Group sales came in at EUR 9.7B vs. EUR 9.97B last year. EBITDA before special items was EUR 1.5B vs. EUR 1.3B last year. Group EBIT came in at (EUR 543M) vs. (EUR 3.8B) last year. Net income amounted to (EUR 963M) vs. (EUR 4.2B) last year. Free cash flow was EUR 596M vs. EUR 1.15B last year. Net financial debt at EUR 32.7B. Speaking on Wednesday while presenting the company’s Quarterly Statement for the third quarter, CEO Bill Anderson highlighted the resilience of the agricultural business and the Pharmaceuticals Division’s topline, while acknowledging that Consumer Health is navigating an increasingly challenging market environment. “Overall, in a pivotal year, we’re in a strong position to deliver the 2025 Group guidance we upgraded last quarter,” he said. Bayer (BAYRY) has also made progress strategically, Anderson noted. Regarding the Pharmaceuticals pipeline, for instance, the company expects to launch Lynkuet, a hormone-free treatment for symptoms associated with the menopause, in the US market this month. Meanwhile, the Crop Science division is focused on executing its Five-Year Framework. Last week, the Plenexos insecticide was launched in Latin America, highlighting the division’s focus on innovative crop solutions, Anderson explained. In addition, the company has further reduced its net financial debt, he noted, and Dynamic Shared Ownership is generating returns, with the operating model delivering benefits on the top and bottom line. “Our organization continues to get leaner and more efficient, and we’re seeing benefits in terms of speed and focus.”